FDA reviews 2 new drugs to reduce prostate cancer

Nov 29, 2010 By MATTHEW PERRONE , AP Health Writer

(AP) -- Health regulators said Monday that two drugs from GlaxoSmithKline and Merck reduce the risk of prostate cancer in men, though scientists questioned the drugs' overall benefit, since the tumors they prevent are usually not life-threatening.

The reviewers for the Food and Administration also complained that the companies only studied a small number of African Americans, who are at high risk for .

The agency will hold a public meeting on the drugs on Wednesday.

U.K.-based PLC has asked the FDA to approve its drug Avodart for a new use against prostate cancer, after research showed a 23 percent reduction in low-grade prostate tumors among men taking the drug.

Merck & Co. of Whitehouse Station, N.J., achieved similar results with its drug Proscar and is asking the FDA to approve labeling about its drug's benefits in reducing prostate cancer risks. Both drugs are already approved to treat enlarged prostate.

But regulators said in an online review Monday that only a small percentage of patients studied were African Americans, who are at increased risk of the disease.

Only 4 percent of Merck's patients were African American, while Glaxo's trial enrolled just 2 percent African American patients.

"The applicability to African-American men is not known due to marked under-representation," states the FDA's review.

FDA's review also raises broader questions about the value of preventing low-grade tumors. According to the FDA, about 80 percent of the tumors the drugs prevent are not aggressive. Because the tumors grow so slowly, they are not considered a threat to senior men with less than 20 years of life expectancy.

While the tumors may not be life threatening, Glaxo has argued that they can lead to unnecessary treatment and biopsies - a procedure where a tiny tissue sample is removed and tested for cancer. About 650,000 men had prostate biopsies last year and seventy percent of the tumors found were low-grade, according to Glaxo.

Some recent studies have suggested prostate cancer is over-diagnosed and over-treated in men - even in men with low-grade tumors. Treatment for the disease can include surgery to remove a , radiation therapy and chemotherapy.

On Wednesday, the FDA will ask a panel out advisers to vote on whether the safety and effectiveness of Avodart and Proscar in preventing prostate cancer. The agency is not required to follow the panel's advice, though it often does.

Explore further: FDA OKs Merck tablet to reduce ragweed allergies

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Study finds possible heart risk with prostate drug

Mar 31, 2010

(AP) -- Full results of a big study testing a drug for preventing prostate cancer show a higher risk of heart failure, a surprise finding that could dampen enthusiasm for expanding its use.

Recommended for you

Study recalculates costs of combination vaccines

19 hours ago

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

22 hours ago

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

Pyridoxine-doxylamine drug safety data lacking

Apr 16, 2014

(Medical Xpress)—The most commonly prescribed drug for pregnant women suffering from morning sickness in their first trimester does not prevent birth defects even though drug safety data says it does, according to research ...

User comments : 0

More news stories

Vietnam battles fatal measles outbreak

Vietnam is scrambling to contain a deadly outbreak of measles that has killed more than 100 people, mostly young children, and infected thousands more this year, the government said Friday.

Continents may be a key feature of Super-Earths

Huge Earth-like planets that have both continents and oceans may be better at harboring extraterrestrial life than those that are water-only worlds. A new study gives hope for the possibility that many super-Earth ...

Researchers successfully clone adult human stem cells

(Phys.org) —An international team of researchers, led by Robert Lanza, of Advanced Cell Technology, has announced that they have performed the first successful cloning of adult human skin cells into stem ...